BioNTech SE (BNTX) Stock Analysis and Metrics

Sector: Healthcare Industry: Biotechnology CIK: 0001776985

P/B 1.05

P/E -34.00

P/S 6.17

Market Cap 22.87 Bn

ROIC (Qtr) 4.80

Div Yield % 0.00

Rev 1y % (Qtr) 29.20

Total Debt (Qtr) 1.10 Bn

Debt/Equity (Qtr) 0.05

About

BioNTech SE, ticker symbol BNTX, is a global next-generation immunotherapy company operating in the healthcare industry. The company specializes in the development and commercialization of mRNA-based vaccines and therapeutics for various diseases, including cancer, infectious diseases, and other serious conditions. BioNTech is headquartered in Mainz, Germany, and has established a strong presence in the global market. BioNTech's main business activities revolve around its proprietary mRNA technology, which enables the development of innovative...

BioNTech SE, ticker symbol BNTX, is a global next-generation immunotherapy company operating in the healthcare industry. The company specializes in the development and commercialization of mRNA-based vaccines and therapeutics for various diseases, including cancer, infectious diseases, and other serious conditions. BioNTech is headquartered in Mainz, Germany, and has established a strong presence in the global market.

BioNTech's main business activities revolve around its proprietary mRNA technology, which enables the development of innovative medicines that can be easily adapted to address emerging diseases. The company's primary products include Comirnaty, its COVID-19 vaccine, and a pipeline of product candidates in various stages of development. BioNTech's oncology pipeline is focused on developing novel immunotherapies that can be used to treat various types of cancer, including immunomodulators, targeted therapies, and mRNA vaccines. Some of the key product candidates in BioNTech's oncology pipeline include BNT111, BNT112, BNT113, BNT114, BNT115, and BNT116.

The company's revenue is generated through the sales of its products and partnerships with other companies and organizations. BioNTech's competitive position is based on its proprietary mRNA technology and its pipeline of product candidates. The company's mRNA technology allows it to rapidly develop and manufacture vaccines and therapeutics, which can be used to address emerging diseases. This competitive advantage sets BioNTech apart from its competitors, including Moderna and CureVac.

BioNTech's customers include governments, healthcare providers, and pharmaceutical companies that are interested in acquiring its mRNA-based vaccines and therapeutics. The company has supplied its COVID-19 vaccine to governments around the world, including the United States, the European Union, and Japan. BioNTech's COVID-19 vaccine is available through healthcare providers in many countries around the world. The company also has partnerships with pharmaceutical companies, including Pfizer, Genmab, and OncoC4, which provide access to additional resources and expertise.

Stock Price Chart

Analysis

Pros

Healthy cash reserves of 11.87B provide 15.51x coverage of short-term debt 765.65M, demonstrating strong liquidity position and minimal refinancing risk.
Strong tangible asset base of 23.05B provides 20.86x coverage of total debt 1.10B, indicating robust asset backing and low credit risk.
Tangible assets of 23.05B provide exceptional 19.30x coverage of deferred revenue 1.19B, showing strong service capability backing.
Retained earnings of 21.49B provide full 63.34x coverage of long-term debt 339.29M, indicating strong internal capital position.
Strong free cash flow of (1.28B) provides 13.81x coverage of acquisition spending (92.35M), indicating disciplined M&A strategy.

Cons

Operating cash flow of (372.71M) barely covers its investment activities of 1.02B, with a coverage ratio of -0.37, indicating heavy reliance on external financing for growth which may not be sustainable in a tighter credit environment.
Investment activities of 1.02B provide weak support for R&D spending of 2.60B, which is 0.39x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
Cash reserves of 11.87B provide limited coverage of acquisition spending of (92.35M), which is -128.57x, suggesting aggressive expansion might strain liquidity if market conditions deteriorate.
Operating cash flow of (372.71M) provides insufficient coverage of deferred revenue obligations of 1.19B, which is -0.31x, raising concerns about future service delivery capabilities.
The company's operating cash flow of (372.71M) shows concerning coverage of stock compensation expenses of 88.71M, with a -4.20 ratio indicating potential earnings quality issues.

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	SMMT	Summit Therapeutics Inc.	1,349.40 Bn	-1,464.17	0.00	0.01 Bn
2	ONC	BeOne Medicines Ltd.	437.43 Bn	6,381.20	87.97	1.90 Bn
3	VRTX	Vertex Pharmaceuticals Inc / Ma	116.09 Bn	31.59	9.90	1.83 Bn
4	REGN	Regeneron Pharmaceuticals, Inc.	78.10 Bn	17.06	5.48	2.71 Bn
5	ALNY	Alnylam Pharmaceuticals, Inc.	55.87 Bn	1,282.42	17.40	3.21 Bn
6	ARGX	Argenx Se	52.85 Bn	35.08	27,559.65	-
7	BNTC	Benitec Biopharma Inc.	41.75 Bn	-998.33	0.00	0.00 Bn
8	INSM	INSMED Inc	37.80 Bn	-31.93	84.56	0.74 Bn

Industry Comparisons

Current Valuation

Metric	Value	Industry
EV to Assets	0.54	12.31
EV to Cash from Ops.	-36.13	23.25
EV to Debt	12.19	738.44
EV to EBIT	-25.81	-9.16
EV to EBITDA	-20.81	6.95
EV to Free Cash Flow [EV/FCF]	-10.56	21.90
EV to Market Cap	0.59	65.67
EV to Revenue	3.63	227.32
Price to Book Value [P/B]	1.05	22.34
Price to Earnings [P/E]	-34.00	-11.77

Dividend Metrics

Metric	Value	Industry
Dividend Coverage Ratio	0.00	-11.94
Dividend Payout Ratio %	0.00	0.16
Dividend per Basic Share	0.00	0.01
FCF Dividend Payout Ratio %	0.00	-0.14
Interest Coverage	-5.64	841.00

Growth Metrics

Metric	Value	Industry
Capex Growth (1y) %	-66.55	-27.13
Cash and Equivalents Growth (1y) %	11.03	734.65
Dividend Growth (1y) %	0.00	0.01
EBIAT Growth (1y) %	-28.49	-46.93
EBITDA Growth (1y) %	19.69	-1.68
EBIT Growth (1y) %	-73.60	-56.45
EBT Growth (1y) %	-75.14	-12.70
EPS Growth (1y) %	-28.69	-28.31
FCF Growth (1y) %	-211.05	-31.90
Gross Profit Growth (1y) %	7.42	226.84

Liquidity Ratios

Metric	Value	Industry
Asset Utilization Ratio	0.17	0.14
Cash Payout Ratio	0.00	0.00
Cash Ratio	4.54	3.85
Current Ratio	7.12	7.27
Debt to Equity Ratio	0.05	0.40
Interest Cover Ratio	-5.64	841.00
Times Interest Earned	-5.64	841.00

Profitability

Metric	Value	Industry
EBITDA Margin %	-1.90	-18,234.31
EBIT Margin %	-11.96	-18,580.80
EBT Margin %	-16.56	-19,488.74
Gross Margin %	82.50	-7.59
Net Profit Margin %	-18.10	-19,439.22

BioNTech SE (NASDAQ: BNTX)